Slowing the progression of chronic hepatitis B

References

• Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—summary of a workshop. Gastroenterology 2001;120(7): 1828–53
   Google Scholar
• Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119(4): 312–23
   PubMed Web of Science ®Google Scholar
• Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114(8): 629–34
   PubMed Web of Science ®Google Scholar
• Lin S-M, Sheen I-S, Chien R-N, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29(3): 971–5
   PubMed Web of Science ®Google Scholar
• Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg- positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334(22): 1422–7
   Google Scholar
• Manesis EK, Hadziyannis SJ. Interferon a treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121(1): 101–9
   PubMed Web of Science ®Google Scholar
• Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997;26(6): 1621–5
   PubMedGoogle Scholar
• Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341(17): 1256–63
   PubMed Web of Science ®Google Scholar
• Lai C-L, Chien R-N, Leung NW. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339(2): 61–8
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Leung NW, Chang T-T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119(1): 172–80
   PubMed Web of Science ®Google Scholar
• Leung NW, Lai C-L, Chang T-T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33(6): 1527–32
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124(1): 105–17
   PubMed Web of Science ®Google Scholar
• Chang T-T, Liaw Y-F, Guan R, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years. (Abstr) Antiviral Ther 2000; 5(Suppl 1):44
   Google Scholar
• Liaw Y-F, Chien R-N, Yeh C-T, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30(2).567–72
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of patients with hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348(9): 808–16
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348(9): 800–7
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang T-T, Lim S-G, et al. Adefovir dipivoxil (ADV) 10 mg for the treatment of patients with HBeAg+ chronic hepatitis B: continued efficacy beyond 48 weeks. (Abstr) Hepatology 2002;36(4 Pt 2):373A
   Google Scholar
• Yang H, Westland CE, Delaney WE, et al. Lack of emerging resistance mutations in 467 HBeAg-negative and HBeAg-positive patients with chronic hepatitis B receiving adefovir dipivoxil for 48 weeks. Presented at the 37th annual meeting of the European Association for the Study of the Liver, April 17–21, 2002, Madrid
   Google Scholar
• Yang H, Westland CE, Delaney WE, et al. Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72 to 136 weeks. (Abstr) Hepatology 2001;34:316A
   Google Scholar
• Heathcote EJ, Jeffers L, Perrillo R, et al. Sustained antiviral response and lack of viral resistance with long-term adefovir dipivoxil therapy in chronic hepatitis B virus infection. Presented at the 37th annual meeting of the European Association for the Study of the Liver, April 17–21, 2002, Madrid
   Google Scholar
• Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication; 48 week preliminary analysis. (Abstr) Hepatology 2002;36(4 Pt 2):374A
   Google Scholar
• Benhamou Y, Bochet M, Thibault V, et al. 96 week efficacy and safety of adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in chronic hepatitis B patients co-infected with HIV. Hepatology 2002;36(4): 638A
   Google Scholar
• Werle B, Wursthorn K, Petersen J, et al. Quantitative analyses of hepatic HBV ccc DNA during the natural history of chronic hepatitis B and adefovir dipivoxil therapy: an international, multicenter study. Hepatology 2002;36(4 Pt 2):296A
   Google Scholar
• Lai C-L, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123(6): 1831–8
   PubMed Web of Science ®Google Scholar
• Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46(4): 562–8
   PubMed Web of Science ®Google Scholar
• Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. Hepatology 2003;38(6): 818–26
   Google Scholar